Stocktoria
Allarity Therapeutics, Inc. ALLR
Allarity Therapeutics, Inc. (ALLR) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $320,000 at a -3509.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ALLR | Allarity Therapeutics, Inc. | 3/9 | — | — | — |
| HIND | Vyome Holdings, Inc | 3/9 | — | — | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 2/9 | — | — | — |
| ABVC | ABVC BIOPHARMA, INC. | 3/9 | -13.52 | — | — |
| IBIO | iBio, Inc. | 3/9 | — | — | — |
| MNOV | MEDICINOVA INC | 1/9 | -18.54 | — | — |
| SCNX | Scienture Holdings, Inc. | 4/9 | -0.88 | — | — |
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
FAQ
Is ALLR financially healthy?
Allarity Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does ALLR pay a dividend?
No, Allarity Therapeutics, Inc. does not currently pay a dividend.
How profitable is ALLR?
In FY2025, Allarity Therapeutics, Inc. had a net margin of -3509.7% and a return on equity of -114.3%.
What is the analyst price target for ALLR?
The average Wall-Street price target for Allarity Therapeutics, Inc. is $10.25, about 632.1% above the recent price, from 1 analysts.
Is ALLR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Allarity Therapeutics, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.